Dogwood Therapeutics, Inc.
DWTX · XNASCIK 1818844fmd_1YWDK4T2N26QZE4K42CAMTZFF8Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Net interest income | (0) | 0 | 0 | 0 | – | – |
| Provision for credit losses | (0) | – | – | – | – | – |
| Net interest income after provision | (0) | – | – | – | – | – |
| Research and development | 0 | 11 | 8 | 2 | 4 | 22 |
| Total operating expenses | 10 | 16 | 12 | 5 | 12 | 28 |
| Operating income | (10) | (16) | (12) | (5) | (12) | (28) |
| Other non-operating income (expense) | (0) | (0) | 0 | 0 | (0) | (6) |
| Income before taxes | (10) | (16) | (12) | (5) | (12) | (34) |
| Income tax expense | – | – | – | – | (0) | 0 |
| Net income from continuing operations | – | – | – | – | (12) | (34) |
| Net income | (10) | (16) | (12) | (5) | (12) | (34) |
| Net income to common shareholders | – | – | – | (5) | (13) | (36) |